(Stroke. 1995;26:503-513.)
© 1995 American Heart Association, Inc.
Articles |
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
From the University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland.
Correspondence to Keith W. Muir, MRCP, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland G11 6NT.
Background Excitotoxic damage due to excess release of neuronal glutamate is hypothesized to play a pivotal role in the pathogenesis of focal cerebral ischemia. Drugs that antagonize excitatory amino acid function are consistently neuroprotective in preclinical models of stroke, and many are now entering clinical trials.
Summary Antagonists of the N-methyl-D-aspartate (NMDA) receptor are furthest advanced in clinical development for stroke. Both noncompetitive (aptiganel hydrochloride, dextrorphan) and competitive (selfotel, d-CPPene) antagonists have undergone tolerability studies in acute stroke and traumatic brain injury. These agents all cause a similar spectrum of neuropsychological symptoms, and several have important cardiovascular effects. Other modulatory sites on the NMDA receptor complex, notably the polyamine and magnesium ion sites, are also the subject of clinical trials. Glycine site antagonists are in early clinical development. Non-NMDA glutamate receptor antagonists remain in preclinical study. Neuroprotection by agents that block glutamate release in vitro may be due to sodium channel blockade in vivo, but some agents (619C89) exhibit neurological effects similar to NMDA antagonists in stroke. The therapeutic index is unknown for different drugs but may be determined by cardiovascular effects, especially hypotension, which may be detrimental after stroke.
Conclusions Excitatory amino acid antagonists are in advanced development in the treatment of stroke and traumatic brain injury. A similar pattern of side effects is apparent with the majority of agents. However, cardiovascular effects may ultimately define therapeutic index for each drug.
Key Words: cerebral ischemia • clinical trials • drug therapy • excitatory amino acids
This article has been cited by other articles:
 |
|
 |
|
  J. P. Buschdorf, L. Li Chew, B. Zhang, Q. Cao, F.-Y. Liang, Y.-C. Liou, Y. T. Zhou, and B. C. Low Brain-specific BNIP-2-homology protein Caytaxin relocalises glutaminase to neurite terminals and reduces glutamate levels. J. Cell Sci., August 15, 2006; 119(Pt 16): 3337 - 3350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sun, D. Chiu, D. Kowal, R. Simon, M. Smeyne, R. S. Zukin, J. Olney, R. Baudy, and S. Lin Characterization of Two Novel N-Methyl-D-aspartate Antagonists: EAA-090 (2-[8,9-Dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic Acid) and EAB-318 (R-{alpha}-Amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic Acid Hydrochloride) J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Pechnick and R. E. Poland Comparison of the Effects of Dextromethorphan, Dextrorphan, and Levorphanol on the Hypothalamo-Pituitary-Adrenal Axis J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Junge, T. Sugawara, G. Mannaioni, S. Alagarsamy, P. J. Conn, D. J. Brat, P. H. Chan, and S. F. Traynelis The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia PNAS, October 28, 2003; 100(22): 13019 - 13024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tarral, P. Dostert, Y. Guillevic, L. Fabbri, I. Rondelli, F. Mariotti, and B. P. Imbimbo Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects J. Clin. Pharmacol., August 1, 2003; 43(8): 901 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Ryu, Y. A. Lee, S. J. Won, J.-H. Noh, S.-Y. Chang, J.-M. Chung, J. S. Choi, C. K. Joo, S. H. Yoon, and B. J. Gwag The Novel Neuroprotective Action of Sulfasalazine through Blockade of NMDA Receptors J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 48 - 56. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
R. Gill, A. Alanine, A. Bourson, B. Buttelmann, G. Fischer, M.-P. Heitz, J. N. C. Kew, B. Levet-Trafit, H.-P. Lorez, P. Malherbe, et al. Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a Novel Subtype-Selective N-Methyl-D-Aspartate Antagonist J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 940 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kawakami, M. Sekiguchi, K. Sato, S. Kozaki, and M. Takahashi Erythropoietin Receptor-mediated Inhibition of Exocytotic Glutamate Release Confers Neuroprotection during Chemical Ischemia J. Biol. Chem., October 12, 2001; 276(42): 39469 - 39475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Williams, X. M. Lu, B. Slusher, and F. C. Tortella Electroencephalogram Analysis and Neuroprotective Profile of the N-Acetylated-alpha -Linked Acidic Dipeptidase Inhibitor, GPI5232, in Normal and Brain-Injured Rats J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 48 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rimpilainen, M. Pokela, K. Kiviluoma, V. Vainionpaa, J. Hirvonen, P. Ohtonen, V. Jantti, V. Anttila, H. Heinonen, and T. Juvonen The N-methyl-D-aspartate antagonist memantine has no neuroprotective effect during hypothermic circulatory arrest: A study in the chronic porcine model J. Thorac. Cardiovasc. Surg., May 1, 2001; 121(5): 957 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-K. Tai, S. E. Blondelle, J. M. Ostresh, R. A. Houghten, and M. Montal An N-methyl-D-aspartate receptor channel blocker with neuroprotective activity PNAS, March 13, 2001; 98(6): 3519 - 3524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Traystman, J. A. Klaus, A. C. DeVries, A. B. Shaivitz, and P. D. Hurn Anticonvulsant Lamotrigine Administered on Reperfusion Fails To Improve Experimental Stroke Outcomes Stroke, March 1, 2001; 32(3): 783 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, A. G. Dyker, A. Sharma, G. A. Ford, M. E. Ardron, and D. G. Grosset Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients : A Dose-Ranging Study Stroke, February 1, 2001; 32(2): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Williams, J. R. Dave, J. B. Phillips, Y. Lin, R. T. McCabe, and F. C. Tortella Neuroprotective Efficacy and Therapeutic Window of the High-Affinity N-Methyl-D-aspartate Antagonist Conantokin-G: In Vitro (Primary Cerebellar Neurons) and In Vivo (Rat Model of Transient Focal Brain Ischemia) Studies J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 378 - 386. [Abstract] [Full Text]
|
|
|
|
|
|
M. Duan, K. Agerman, P. Ernfors, and B. Canlon From the Cover: Complementary roles of neurotrophin 3 and a N-methyl-D-aspartate antagonist in the protection of noise and aminoglycoside-induced ototoxicity PNAS, June 20, 2000; 97(13): 7597 - 7602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Tortella, P. Britton, A. Williams, X. C. M. Lu, and A. H. Newman Neuroprotection (Focal Ischemia) and Neurotoxicity (Electroencephalographic) Studies in Rats with AHN649, a 3-Amino Analog of Dextromethorphan and Low-Affinity N-Methyl-D-Aspartate Antagonist J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 399 - 408. [Abstract] [Full Text]
|
|
|
|
|
|
R. Schmid-Elsaesser, E. Hungerhuber, S. Zausinger, A. Baethmann, H.-J. Reulen, and J. A. Zivin Combination Drug Therapy and Mild Hypothermia : A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia • Editorial Comment: A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia Stroke, September 1, 1999; 30 (9): e1891 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Davis and D. Barer Neuroprotection in acute ischaemic stroke. II: Clinical potential Vascular Medicine, August 1, 1999; 4(3): 149 - 163. [Abstract] [PDF]
|
|
|
|
 |
|
 B. H. Sirin, E. Coskun, L. Yilik, R. Ortac, H. Sirin, and C. Tetik Neuroprotective effects of preischemia subcutaneous magnesium sulfate in transient cerebral ischemia Eur. J. Cardiothorac. Surg., July 1, 1999; 14(1): 82 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Dyker and K. R. Lees Safety and Tolerability of GV150526 (a Glycine Site Antagonist at the N-Methyl-D-Aspartate Receptor) in Patients With Acute Stroke Stroke, May 1, 1999; 30(5): 986 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, W. M. Clark, R. P. Atkinson, K. Madden, J. L. Data, and M. J. Whitehouse Dose Escalation Study of the NMDA Glycine-Site Antagonist Licostinel in Acute Ischemic Stroke Stroke, March 1, 1999; 30(3): 508 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Heresco-Levy, D. C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia Arch Gen Psychiatry, January 1, 1999; 56(1): 29 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Slyter Ethical Challenges in Stroke Research Stroke, August 1, 1998; 29(8): 1725 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and J. Bogousslavsky Further Evolution Toward Effective Therapy for Acute Ischemic Stroke JAMA, April 22, 1998; 279(16): 1298 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Dyker and K. R. Lees Duration of Neuroprotective Treatment for Ischemic Stroke Stroke, February 1, 1998; 29(2): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tatlisumak, K. Takano, M. R. Meiler, M. Fisher, and W. D. Dietrich A Glycine Site Antagonist, ZD9379, Reduces Number of Spreading Depressions and Infarct Size in Rats With Permanent Middle Cerebral Artery Occlusion • Editorial Comment Stroke, January 1, 1998; 29(1): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Parsons, W. Danysz, G. Quack, S. Hartmann, B. Lorenz, C. Wollenburg, L. Baran, E. Przegalinski, W. Kostowski, P. Krzascik, et al. Novel Systemically Active Antagonists of the Glycine Site of the N-Methyl-D-aspartate Receptor: Electrophysiological, Biochemical and Behavioral Characterization J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1264 - 1275. [Abstract] [Full Text]
|
|
|
|
|
|
G. Fischer, V. Mutel, G. Trube, P. Malherbe, J. N. C. Kew, E. Mohacsi, M. P. Heitz, and J. A. Kemp Ro 25-6981, a Highly Potent and Selective Blocker of N-Methyl-D-aspartate Receptors Containing the NR2B Subunit. Characterization in Vitro J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1285 - 1292. [Abstract] [Full Text]
|
|
|
|
|
|
K. Takano, T. Tatlisumak, J. E. Formato, R. A. D. Carano, A. G. Bergmann, L. M. Pullan, T. M. Bare, C. H. Sotak, and M. Fisher Glycine Site Antagonist Attenuates Infarct Size in Experimental Focal Ischemia : Postmortem and Diffusion Mapping Studies Stroke, June 1, 1997; 28(6): 1255 - 1263. [Abstract] [Full Text]
|
|
|
|
|
|
M. Z. Onal, F. Li, T. Tatlisumak, K. W. Locke, B. W. Sandage Jr, and M. Fisher Synergistic Effects of Citicoline and MK-801 in Temporary Experimental Focal Ischemia in Rats Stroke, May 1, 1997; 28(5): 1060 - 1065. [Abstract] [Full Text]
|
|
|
|
|
|
R. Newcomb, X. Sun, L. Taylor, N. Curthoys, and R. G. Giffard Increased Production of Extracellular Glutamate by the Mitochondrial Glutaminase following Neuronal Death J. Biol. Chem., April 25, 1997; 272(17): 11276 - 11282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Davalos, J. Castillo, J. Serena, and M. Noya Duration of Glutamate Release After Acute Ischemic Stroke Stroke, April 1, 1997; 28(4): 708 - 710. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Witkin, T. D. Steele, and L. G. Sharpe Effects of Strychnine-Insensitive Glycine Receptor Ligands in Rats Discriminating Dizocilpine or Phencyclidine from Saline J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 46 - 52. [Abstract] [Full Text]
|
|
|
|
|
|
P. J. Dorman and P. A.G. Sandercock Considerations in the Design of Clinical Trials of Neuroprotective Therapy in Acute Stroke Stroke, September 1, 1996; 27(9): 1507 - 1515. [Full Text]
|
|
|
|
|
|
J. Castillo, A. Davalos, J. Naveiro, and M. Noya Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic Stroke Stroke, June 1, 1996; 27(6): 1060 - 1065. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Carter, M. Grauert, U. Pschorn, W. D. Bechtel, C. Bartmann-Lindholm, Y. Qu, T. Scheuer, W. A. Catterall, and T. Weiser Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL PNAS, April 25, 2000; 97(9): 4944 - 4949. [Abstract] [Full Text] [PDF]
|
|